Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type

SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) protein is the target for the antiviral drug Remdesivir (RDV). With RDV clinical trials on COVID-19 patients showing a reduced hospitalisation time. During the spread of the virus, the RdRp has developed several mutations, with the most frequent being A...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammad, Anwar, Al-Mulla, Fahd, Wei, Dong-Qing, Abubaker, Jehad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301449/
https://www.ncbi.nlm.nih.gov/pubmed/34206274
http://dx.doi.org/10.3390/biom11070919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301449/
https://www.ncbi.nlm.nih.gov/pubmed/34206274
http://dx.doi.org/10.3390/biom11070919

Ejemplares similares